CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...
Zacks.com on MSN2d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...
AZoLifeSciences on MSN2d
Integrating CRISPR and biomaterials engineering: Paving the way for safer gene therapiesLehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback